IPEC-Americas is working with the IQ Consortium on how to foster a process that would promote quicker acceptance and approval of novel excipients. They are reaching out to member companies through a short survey for input on where and why novel excipients can improve drug delivery and who would be interested in participating on the joint IPEC/IQ effort. A companion survey is gathering information on excipients used as atypical actives, and the related concerns or questions that have been received from customers or regulatory authorities.
[membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
